Čoupková, H, Skřičková, J, Hejduk, K, Bortlíček, Z, Kadlec, B, Salajka, F, Pešek, M, Kolek, V, Koubkova, L, Sixtova, D, Zatloukal, P, Roubec, J, Zemanová, M, Vyzula, R, Špelda, S. Characteristics of advanced NSCLC patients with at least 6 months erlotinib treatment duration in Czech Republic. 2012 ASCO Annual Meeting, Chicago, 1.-5. 6. 2012
Čoupková, H, Skřičková, J, Hejduk, K, Bortlíček, Z, Kadlec, B, Salajka, F, Pešek, M, Kolek, V, Koubkova, L, Sixtova, D, Zatloukal, P, Roubec, J, Zemanová, M, Vyzula, R, Špelda, S. Characteristics of advanced NSCLC patients with at least 6 months erlotinib treatment duration in Czech Republic. 2012 ASCO Annual Meeting, Chicago, 1.-5. 6. 2012